The two-week regimen is a breakthrough in the treatment of postpartum depression. The neuroactive steroid takes effect in as little as three days and could be available for use by November.
is taken for just two weeks and recently completed its third trial study, displaying continued promise., approximately 200 women taking a 50-milligram dose for two weeks experienced significant improvements in depressive symptoms. Around 60 percent of those taking zuranolone reported a 50 percent or better improvement in their depressive symptoms after two weeks, with some participants reporting a difference in as little as three days.
How are such quick results possible? Unlike antidepressents, most of which are slow-acting selective serotonin reuptake inhibitors , zuranolone, is a version of a naturally occurring substance in the body called allopregnanolone—a neuroactive steroid that is metabolizes the hormone progesterone. Levels of allopregnanolone can rise dramatically during pregnancy and then abruptly drop after childbirth, potentially contributing to postpartum depression.
“Neuroactive steroids are naturally made in the brain and are breakdown products of progesterone that protect brain networks from the damaging effects of stress and maintain healthy brain network functioning,” Dr. Kristina Deligiannidis, the lead author of both studies told“It saved my life. It saved my marriage. It saved my kids,” Sahar McMahon, a member of the trial study, said of her experience taking zuranolone.
Now that the drug has been approved by the FDA, it will undergo a 90-day review by the Drug Enforcement Agency before being potentially released in November. Marketed under the name ZurZuvae, The makers of zuranolone have yet to set a price for the medication.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA approves first pill specifically designed to treat postpartum depressionFDA APPROVED: Doctors say postpartum depression is a condition that can start during pregnancy with symptoms such as feelings of sadness, guilt, loss of energy and difficulty sleeping.
続きを読む »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
続きを読む »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
続きを読む »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
続きを読む »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
続きを読む »
FDA approves first postpartum depression pill in the USThe US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression.
続きを読む »